Binaytara shared a post on LinkedIn:
” ‘Instead of being a late-line option as a rescue for patients, ADCs will become a curative option to get rid of cancer, not to see it anymore, to prevent recurrences. It’s going to be the standard chemotherapy in the future.’
The center of gravity for ADCs is shifting. This was a theme that came through clearly in Dr. Paolo Tarantino’s keynote at our Detroit 2026 Hematology and Oncology Practice Symposium.
Until recently, most of us encountered ADCs as later-line options after standard chemotherapy had been exhausted. That’s changing fast. The implication for practice is significant: ADCs are no longer just a rescue strategy. In several disease states, they’re moving toward becoming the backbone of curative-intent therapy.
What do you think will see the next major early-line shift?
Read more about Dr Tarantino’s keynote.”
Other articles about Binaytara on OncoDaily.